TARS

Tarsus Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↑ 7/10
  • Value↓ 2/10
Tarsus Pharmaceuticals sales and earnings growth
TARS Growth
Good
  • Revenue Y/Y↑ 106.49%
  • EPS Y/Y↑ 58.46%
  • FCF Y/Y↑ 56.72%
Tarsus Pharmaceuticals gross and profit margin trends
TARS Profitability
Neutral
  • Gross margin ↑ 93.50%
  • EPS margin↓ -9.00%
  • ROIC 5Y↓ -76.17%
Tarsus Pharmaceuticals net debt vs free cash flow
TARS Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -4.0

Tarsus Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks